Hyderabad News Desk

Creative Biolabs Introduces Innovative Antibody-Drug Conjugate Development Services

 Breaking News
  • No posts were found

Creative Biolabs Introduces Innovative Antibody-Drug Conjugate Development Services

December 26
19:05 2023
Leveraging years of expertise and cutting-edge technology, Creative Biolabs commits to delivering state-of-the-art solutions for ADC development, positioning itself as a frontrunner in the field.

New York, USA – December 19, 2023 – ADCs represent a class of targeted cancer therapies that merge the specificity of antibodies with the potency of cytotoxic drugs. They exhibit tremendous potential for delivering potent drugs directly to cancer cells while minimizing side effects compared to traditional chemotherapy. Creative Biolabs recognizes the immense promise of ADCs in revolutionizing cancer treatment and is dedicated to contributing to the advancement of this field.

“We’ve schemed the one-stop antibody-drug conjugate pipeline,” according to a scientist at Creative Biolabs, “integrating antibody design, conjugation, and in vitro & in vivo analysis.”

A pivotal component is the development of payloads. By harnessing the exclusive DrugLnk organic synthesis platform, Creative Biolabs delivers the most suitable payloads for researchers’ specific needs, including microtubule toxins, DNA toxins, transcription toxins, inhibitors, and novel payloads like nano-carriers, protein toxins, and toxic proteins, all of which have outstanding properties in cytotoxic efficacy, internalization and drug release, size, water solubility, and stability.

The use of DrugLnk extends to drug-linker synthesis services. Developing an ADC usually requires the warhead and drug-linker to be assembled before they are conjugated to the antibody. Creative Biolabs helps with the selection of a linker that plays a pivotal role in connecting the antibody and the payload and facilitating drug release. Available options cover pH-sensitive linkers, disulfide linkers, peptide linkers, ß-glucuronide linkers, and non-cleavable linkers.

“Full-scale analyses should be conducted before a candidate can move on,” according to the scientist.

Thus, a comprehensive analysis system has been set up to fully validate a candidate in terms of its biochemical, efficacy, and cytotoxicity profiles, among which the conjugate DAR (drug to antibody ratio) is one of the critical aspects to illustrate the efficacy and safety of an ADC-by assessing the amount of payload delivered to the targeting issues. Case by case, Creative Biolabs adopts ultraviolet-visible (UV/Vis) spectroscopy, hydrophobic interaction chromatography (HIC), reversed phase high-performance liquid chromatography (RP-HPLC), or liquid chromatography coupled with electrospray ionization mass spectrometry (LC-ESI-MS).

“Regarding the recent enthusiasm for seeking a high-throughput generation and purification method that can significantly enhance the efficiency of ADC synthesis, I’d like to highlight one of our protocols regarding the preparation of dual-labeled and site-specific antibody and Fab conjugates by solid-phase,” added the scientist, “in which some solid-phase conjugation methods for the preparation of dual-labeled antibodies and Fab conjugates using antibodies and engineered cysteines are introduced. This protocol can assist our customers in gaining a better understanding of how to perform conjugation through solid-phase coupling reactions.”

At Creative Biolabs, client success is always the top priority. The company is committed to delivering tailor-made solutions that meet the unique requirements of each project. With their extensive experience, state-of-the-art technology, and industry-leading expertise, Creative Biolabs is poised to drive innovation and make significant contributions to the ADC field.

For more information about Creative Biolabs and their ADC development services, please visit their website at https://www.creative-biolabs.com/adc.

About

Creative Biolabs is a leading custom service provider with extensive experience in various ADC-related research and manufacturing fields. With a team of experts and state-of-the-art facilities, Creative Biolabs is committed to supporting scientists and researchers in accelerating their research and development programs.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/adc

Categories